Loading…
Reported covered position: CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Combating Organized Retail Crime Act of 2025
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act
Combating Organized Retail Crime Act of 2025
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
WHOOP via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Health tech, removal of barrier / maintain existing flexibility to allow access to health tech wellness products
lobbying related to Medicare coverage and health technology
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
| HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) |
| 18 |
| 2022–2026 |
| PHRMA | 18 | 2022–2026 |
| SAREPTA THERAPEUTICS | 18 | 2022–2026 |
| ABBOTT (FORMERLY KNOWN AS ALERE INC.) | 17 | 2022–2026 |
| ABBVIE, INC. | 17 | 2022–2026 |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) | 17 | 2022–2026 |
| AMERICAN INVESTMENT COUNCIL | 17 | 2023–2026 |
| AMGEN, INC. | 17 | 2022–2026 |
| AMYLYX PHARMACEUTICALS | 17 | 2022–2026 |
| BOEHRINGER INGELHEIM | 17 | 2022–2026 |
| CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) | 17 | 2022–2026 |
| ELI LILLY AND COMPANY | 17 | 2022–2026 |
| FLAGSHIP PIONEERING | 17 | 2022–2026 |
| FOUNDATION MEDICINE | 17 | 2022–2026 |
| GILEAD SCIENCES, INC. | 17 | 2022–2026 |
| LINCARE | 17 | 2022–2026 |
| MERCK | 17 | 2022–2026 |
| NEUROCRINE BIOSCIENCES, INC | 17 | 2022–2026 |
| NOVOCURE INC. | 17 | 2022–2026 |
| SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | 17 | 2022–2026 |
| NOVARTIS | 16 | 2023–2026 |
| ACCENTURE FEDERAL SERVICES | 15 | 2022–2026 |
| BD (BECTON, DICKINSON AND COMPANY) | 15 | 2022–2026 |
| THE AMPUTEE COALITION | 15 | 2022–2026 |
| VALNEVA USA, INC | 15 | 2023–2026 |
| AMAZON.COM SERVICES LLC | 14 | 2024–2026 |
| AMERICAN OSTEOPATHIC ASSOCIATION | 14 | 2022–2025 |
| EXCELLUS HEALTH PLAN INC. | 14 | 2023–2026 |
| GENTIVA (FORMERLY REPORTED AS HUMANA & KINDRED AT HOME) | 14 | 2022–2025 |
| JAZZ PHARMACEUTICALS INC. | 13 | 2022–2025 |
| LANTHEUS | 13 | 2024–2026 |
| SAS | 13 | 2022–2025 |
| AMNEAL PHARMACEUTICALS, INC. | 12 | 2024–2026 |
| ASTELLAS PHARMA US, INC. | 12 | 2024–2026 |
| BRISTOL MYERS SQUIBB | 12 | 2022–2025 |
| GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) | 11 | 2022–2025 |
| AIS HEALTHCARE | 10 | 2022–2024 |
| NOVO NORDISK, INC. | 10 | 2022–2024 |
| THORN RUN PARTNERS (ON BEHALF OF THE PARTNERSHIP TO IMPROVE PATIENT CARE) | 10 | 2022–2024 |
| TRIPLE-S MANAGEMENT CORPORATION | 10 | 2022–2024 |
| QUEST DIAGNOSTICS | 9 | 2023–2024 |
| ADVAMED | 8 | 2024–2025 |
| MEDICALLY HOME | 8 | 2022–2024 |
| WHOOP | 7 | 2025–2026 |
| 10X GENOMICS | 6 | 2022–2023 |
| BLUEPRINT BIOSECURITY ACTION | 6 | 2025–2026 |
| HANSA BIOPHARMA | 6 | 2024–2025 |
| HEALTHCARE LEADERSHIP COUNCIL | 6 | 2022–2023 |
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (MITA) | 6 | 2022–2023 |
| OCTAVIANT FINANCIAL INC. | 6 | 2023–2024 |
| ONE MEDICAL | 6 | 2022–2023 |
| ADVOCATES FOR COMMUNITY HEALTH | 5 | 2023 |
| EVERGREEN NEPHROLOGY | 5 | 2024 |
| HEALTH CARE SERVICE CORPORATION | 5 | 2022–2023 |
| Hims & Hers Health, Inc. | 5 | 2023–2024 |
| RAYNER SURGICAL INC. | 5 | 2026 |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 4 | 2022–2023 |
| ELEVANCE HEALTH, INC (F.K.A. ANTHEM, INC. & WELLPOINT, INC.) | 4 | 2022–2023 |
| LONGEVITY HEALTH PLAN | 4 | 2022–2023 |
| NATIONAL SEATING & MOBILITY | 4 | 2024 |
| AMERICAN ACADEMY OF PEDIATRICS | 3 | 2024 |
| CULINA HEALTH | 2 | 2026 |
| BAXTER | 1 | 2022 |
| HEALTH GORILLA | 1 | 2023 |
| MALLINCKRODT PHARMACEUTICALS | 1 | 2022 |
| OPTION CARE HEALTH | 1 | 2023 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 1 | 2022 |
| SIGNIFY (F.K.A. REMEDY BPCI PARTNERS, LLC) | 1 | 2022 |
Ensuring Community Access to Pharmacist Services Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program for Indians Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
ISLET Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
ISLET Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Military Next-Gen Collision Avoidance Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Military Next-Gen Collision Avoidance Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Health Care Cybersecurity and Resiliency Act of 2026
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act
Break Up Big Medicine Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program for Indians Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program for Indians Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Bipartisan Health Care Act
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.
American Relief Act, 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3435 - the Charitable Act S. 566 - the Charitable Act H.R. 10545 American Relief Act of 2025 H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes
American Relief Act, 2025
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8467 - Farm, Food, and National Security Act of 2024 H.R. 10545 - American Relief Act of 2025 Drug safety, prescription drug abuse, value of prescription drugs
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicare reimbursement issues, S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicare reimbursement issues, S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicare reimbursement issues, S. 1544/H.R.1199 FIND Act
Facilitating Innovative Nuclear Diagnostics Act of 2023
Client: LANTHEUS · Firm: TARPLIN, DOWNS & YOUNG, LLC
Medicare reimbursement issues, Medicare payment for radiopharmaceuticals S. 1544/H.R.1199 FIND Act
PSA Screening for HIM Act
Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing
PSA Screening for HIM Act
Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing
PSA Screening for HIM Act
Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing
Special Diabetes Program Reauthorization Act of 2023
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act
Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Issues pertaining to NIH appropriations for FY25
Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Further Consolidated Appropriations Act, 2024
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4336, the Consolidated Appropriations Act, 2024 (P.L. 118-42) H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47) Drug safety, prescription drug abuse, value of prescription drugs, expiring healthcare extenders
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: AMERICAN INVESTMENT COUNCIL · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care.
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: AMERICAN INVESTMENT COUNCIL · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: AMERICAN INVESTMENT COUNCIL · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information.
Client: AMERICAN INVESTMENT COUNCIL · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
Charitable Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3435 - the Charitable Act S. 566 - the Charitable Act H.R. 10545 American Relief Act of 2025 H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
H.R. 3262 H.R. 3561 Legislation affecting the regulation of private equity, and other proposals related to equitable treatment of private equity in health care.
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
SCREENS for Cancer Act of 2024
Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED
SCREENS for Cancer Act of 2024
Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Summer Meals REACH Act of 2023
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4336, the Consolidated Appropriations Act, 2024 (P.L. 118-42) H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47) Drug safety, prescription drug abuse, value of prescription drugs, expiring healthcare extenders
Consolidated Appropriations Act, 2024
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Consolidated Appropriations Act, 2024
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Issues pertaining to NIH appropriations for FY25
Consolidated Appropriations Act, 2024
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Preparing for All Hazards and Pathogens Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Preparing for All Hazards and Pathogens Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
2026 · third_quarter · Q3
Lobbying related to pharmaceutical and Medicare/Medicaid policy
Lobbying related to pharmaceutical policy
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAREPTA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to rare disease policy and coverage
Lobbying related to rare disease policy
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
federal budget issues
Lobbying related to pharmaceutical policy and Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RAYNER SURGICAL INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare payment policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHRMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical and Medicare & Medicaid policy
Lobbying related to pharmaceutical policy
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVOCURE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to regulatory policy
Lobbying related to Medicare coverage and reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to trade
Lobbying related to pharmaceutical policy
Federal budget issues
Lobbying related to pharmaceutical policy
NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
telehealth, mental health, prescription drug pricing, payment reform
federal budget issues
IRA, prescription drug pricing, payment reform, innovation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Federal budget issues
IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA
IRA, Medicare and Medicaid payment and coverage issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LINCARE via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to Medicare coverage and reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LANTHEUS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare & Medicaid and pharmaceutical policy
Federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FOUNDATION MEDICINE via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to diagnostics and health care policy.
Lobbying related to diagnostics and health care policy and payment issues
supply chain
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ELI LILLY AND COMPANY via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
federal budget issues
Medicare & Medicaid payment and coverage issues, lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EXCELLUS HEALTH PLAN, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Medicare Advantage, Medicare reimbursement and payment issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical supply
Federal budget issues
lobbying related to Medicare and Medicaid
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BOEHRINGER INGELHEIM via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare & Medicaid coverage and payment issues
federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues
Federal budget issues
Lobbying related to pharmaceutical, tax, and health care policy
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Medicare & Medicaid coverage and reimbursement issues
Lobbying related to health care policy and research funding
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care policy and research funding
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTELLAS PHARMA US, INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
rare disease and access to innovation
rare disease and access to innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to domestic pharmaceutical supply
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy and Medicare policy
federal budget issues
Lobbying related to pharmaceutical policy and health care access
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy and Medicare and Medicaid policy
federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN INVESTMENT COUNCIL via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care investment policy.
Lobbying related to health care investment policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care policy, access, and coverage
federal budget issues
Lobbying related to health care policy, access and coverage, and Medicare & Medicaid policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMAZON.COM SERVICES LLC via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to health care policy, technology, and Medicare policy
Lobbying related to health care policy, technology, Medicare policy, and FDA policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBOTT (FORMERLY KNOWN AS ALERE INC.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
issues related to national trade
Lobbying related to health care policy, Medicare reimbursement
Lobbying related to health care policy, Medicare reimbursement
ABBVIE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA
Part B, Part D, drug pricing and access, negotiation,
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RAYNER SURGICAL INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · 2A
Lobbying related to Medicare payment policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CULINA HEALTH via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · 2T
Medicare reimbursement for nutritional therapy
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to disease research, and innovation
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical and health care policy
Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues
Federal budget issues
HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule General Issues Related to Supply Chain Ownership
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
AMAZON.COM SERVICES LLC via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to health care policy, technology, and Medicare policy
Lobbying related to health care policy, technology, Medicare policy, and FDA policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBVIE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Part B, Part D, drug pricing and access, negotiation,
federal budget issues
drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
IRA, Medicare and Medicaid payment and coverage issues
Federal budget issues
IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Federal budget issues
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
AMERICAN INVESTMENT COUNCIL via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care investment policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care policy and research funding
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHRMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · 2A
Lobbying related to pharmaceutical and Medicare & Medicaid policy
Federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHRMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical and Medicare & Medicaid policy
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
EXCELLUS HEALTH PLAN, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Medicare Advantage, Medicare reimbursement and payment issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LANTHEUS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
WHOOP via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Health tech, removal of barrier / maintain existing flexibility to allow access to health tech wellness products
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAREPTA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to rare disease policy
Lobbying related to rare disease policy and coverage
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
federal budget issues
Lobbying related to pharmaceutical policy and Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RAYNER SURGICAL INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare payment policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVOCURE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare coverage and reimbursement
Lobbying related to regulatory policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
telehealth, mental health, prescription drug pricing, payment reform
IRA, prescription drug pricing, payment reform, innovation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LINCARE via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare coverage and reimbursement policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Federal budget issues
Lobbying related to Medicare & Medicaid and pharmaceutical policy
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ELI LILLY AND COMPANY via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Medicare & Medicaid payment and coverage issues, lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical supply
Federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BOEHRINGER INGELHEIM via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
Lobbying related to Medicare & Medicaid coverage and payment issues
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to pharmaceutical policy and Medicare and Medicaid policy
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
rare disease and access to innovation
rare disease and access to innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy and Medicare policy
Lobbying related to pharmaceutical policy and health care access
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to health care policy, access and coverage, and Medicare & Medicaid policy
Lobbying related to health care policy, access, and coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBOTT (FORMERLY KNOWN AS ALERE INC.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to health care policy, Medicare reimbursement
issues related to national trade
AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to domestic pharmaceutical supply
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical and Medicare/Medicaid policy
Lobbying related to pharmaceutical policy
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FOUNDATION MEDICINE via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
supply chain
Lobbying related to diagnostics and health care policy.
Lobbying related to diagnostics and health care policy and payment issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
RAYNER SURGICAL INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Medicare payment for non-opioid pain management for cataract surgery; Medicare quality measurement issues.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
RAYNER SURGICAL INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · RR
Medicare payment for non-opioid pain management for cataract surgery; Medicare quality measurement issues
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CULINA HEALTH via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Medicare reimbursement for nutritional therapy
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
VERTEX PHARMACEUTICALS INCORPORATED via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, drug pricing in federal programs, opioid alternative medicines, awareness of rare kidney disorders
Medicare & Medicaid payment and coverage issues
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
IRA, pharmaceuticals access and affordability, drug pricing in federal programs, HCV screening, drug pricing and access, HIV, oncology, PAHPA reauthorization
Medicare & Medicaid payment and coverage issues
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
rare disease and access to innovation
rare disease and access to innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WHOOP via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
health tech, removal of barriers / maintain existing flexibility to allow access to health tech wellness products
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHRMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Federal budget issues
IRA, supply chain integrity, innovation, drug pricing in federal programs, transparency
Medicare & Medicaid payment and coverage issues, transparency, drug pricing in federal programs
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAREPTA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
innovation, Duchenne Muscular Dystrophy, platform technologies, value based contracting, gene therapy
federal budget issues
Medicaid drug rebate program, coverage, state program operations, waivers, gene therapy, value based contracting
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
bio pharmaceutical reimbursement issues, IRA
tariffs
MINI Act, IRA, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies, supply chain, drug pricing and drug discount programs in federal programs, international drug reference pricing
CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
General issues related to drug shortages, supply chain
Federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBOTT (FORMERLY KNOWN AS ALERE INC.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Medicare reimbursement, Medicare competitive bidding for diabetics supplies, diagnostics, self-testing, nutrition, emerging medical device technology, national coverage decisions
federal budget issues
issues related to national trade
ABBVIE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Part B, Part D, drug pricing and access, negotiation,
drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ACCENTURE FEDERAL SERVICES via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · 1T
changes to the organ national transplant program
federal budget issues
operational and contract issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Medicare & Medicaid policy and reimbursement issues, MCED
federal budget issues
IRA, SCREENS for Cancer Act, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN INVESTMENT COUNCIL via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
Legislation affecting the regulation of private equity and other proposals related to equitable treatment of private equity in health care, private equity ownership with healthcare entities
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
care planning, home and community based care, innovation, NAPA, BOLD Act, Advancing America's Interests Act, ADAPT Act, ASAP Act
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BD (BECTON, DICKINSON AND COMPANY) via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · 1T
federal budget issues
supply chain, US competitiveness
IRA, diagnostics, supply chain, privacy
BLUEPRINT BIOSECURITY ACTION via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · 1T
health care preparedness
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
IRA, innovation, drug pricing in federal programs, orphan drugs, PAPHA reauthorization, competitiveness, supply chain, vaccine access and coverage
Medicare & Medicaid payment and coverage issues
Federal budget issues
ASTRAZENECA via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
Medicare and Medicaid drug and coverage issues, orphan drugs
IRA, drug pricing in federal programs, orphan drug issues, oncology, transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTELLAS PHARMA US, INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
menopause, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs
IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · first_quarter · Q1
federal budget issues
drug shortages, critical medicines limited to antibiotics and antimicrobials
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
lobbying related to trade issues
Lobbying related to pharmaceutical and health care policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Lobbying related to pharmaceutical, tax, and health care policy
lobbying related to trade issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Lobbying related to trade
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Lobbying related to health care policy, Medicare reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
infant formula, diagnostics, regulation, supply chain, changes to the organ national transplant program, LDTs, Future Pharmacy, physician fee schedule reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Medicare coverage and reimbursement, diagnostics
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
vaccine policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE